Sangamo Therapeutics, a clinical-stage genomic medicine company, focuses on transforming patient lives with serious disease treatments. They have several product candidates in various stages of development: ST-920 (Fabry disease), TX200 (kidney transplant rejection prevention), SB-525 (hemophilia A), and BIVV003 (sickle cell disease). Their preclinical products focus on autoimmune disorders and neurological diseases. The company has partnerships with several organizations, including Biogen, Kite Pharma, Pfizer, Sanofi, Novartis, Shire, Dow AgroSciences, Sigma-Aldrich, Genentech, and Open Monoclonal Technology.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.1 |